Corporate Banner
Satellite Banner
Medicinal Chemistry
Scientific Community
Become a Member | Sign in
Home>News>This Article

MorphoSys Strengthens Clinical Development Organization with Three Management Appointments

Published: Monday, December 23, 2013
Last Updated: Sunday, December 22, 2013
Bookmark and Share
Appointment of Dr. Gabriele Elbl, Dr. Ludger Langer and Dr. Steffen Heeger.

MorphoSys AG has announced that it has completed the expansion of its senior clinical development team by appointing Dr. Gabriele Elbl as Head of Regulatory Affairs, Dr. Ludger Langer as Head of Clinical Operations and Project Management and most recently Dr. Steffen Heeger as Head of Clinical Research.

Gabriele Elbl joined MorphoSys after working for more than 20 years in small and large pharmaceutical companies. During this time she gained a deep understanding of all regulatory aspects of product development, both for the US and the EU.

Dr. Elbl has extensive experience of development programs for biologics through interactions with both the American Food and Drug Administration (FDA) and the European Medicines Agency (EMA). Most recently she held the position of Senior Vice President, Regulatory Affairs at Wilex AG, Munich.

Prior to that she worked as a Scientific Administrator at the EMA, London, and served as Head of Pharmaceutical Department at Sanofi Winthrop in Munich. Dr. Elbl studied pharmacy and received a PhD in Pharmaceutical Biology from the Ludwig-Maximilian-University, Munich.

Ludger Langer joined MorphoSys from PRA International. He brings almost 20 years of clinical operations and project management experience to MorphoSys. Dr. Langer held several positions of increasing seniority in Clinical Operations and Project Management with a focus on planning and execution of multiregional clinical trials.

Prior to joining MorphoSys, Dr. Langer was Vice President, Clinical Operations, Europe, Asia-Pacific and Africa at PRA International. Dr. Langer studied pharmacy and received a PhD from the Goethe University, Frankfurt/Main.

Steffen Heeger is an oncologist with deep experience in oncology drug development from his past ten years at Merck Serono, where he was Head of Medical Affairs and where he led the Global Clinical Development Team for Erbitux®. Dr. Heeger studied Medicine in Freiburg, Heidelberg and Mannheim and continued his medical training at the Clinic of Hematology/Oncology of the University of Heidelberg.

During this time he was also a scientist at the German Cancer Research Center (DKFZ) in Heidelberg where he worked on the development of antibody conjugates. He received a PhD in Medicine from the University of Heidelberg.

"We are very pleased to have gained three outstanding individuals for these key positions within the MorphoSys development organization," explained Dr. Arndt Schottelius, Chief Development Officer of MorphoSys AG. "The appointment of Gabriele Elbl and Ludger Langer earlier this year and most recently Steffen Heeger already had a significant impact on our development capabilities and underscores our strong commitment to the further expansion, development and commercialization of our proprietary drug portfolio."

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,600+ scientific posters on ePosters
  • More than 3,800+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

MorphoSys Reports Promising Pre-clinical Data for MOR202
Combination studies to be presented at Annual Meeting of the American Society of Clinical Oncology.
Tuesday, May 24, 2011
MorphoSys Announces Clinical Milestone from Strategic Alliance
The announcement represents the second HuCAL-derived antibody to achieve this stage during the course of 2010.
Friday, July 02, 2010
MorphoSys Announces Clinical Milestone from Centocor Ortho Biotech
The milestone marks the initiation of a phase 1 clinical trial of a HuCAL-derived antibody.
Thursday, June 24, 2010
AbD Serotec Enters New Growth Area
Recombinant anti-idiotype antibodies as important research and drug development tools.
Tuesday, May 18, 2010
MorphoSys and WACKER Expand Cooperation to Use WACKER's ESETEC® Technology
MorphoSys will now be able to use the WACKER technology for the production of antigen material.
Thursday, February 04, 2010
MorphoSys Enrolls First Patient in Phase 1b/2a Clinical Trial for MOR103 Program in Rheumatoid Arthritis
Company's MOR103 program is a fully human HuCAL antibody directed against GM-CSF being developed for inflammatory diseases.
Thursday, January 21, 2010
MorphoSys Receives Regulatory Approval to Start Phase 1b/2a Clinical Trial for MOR103 Program
Germany's Paul-Ehrlich-Institute approves clinical trial in rheumatoid arthritis patients.
Monday, November 16, 2009
MorphoSys and Daiichi Sankyo Forge Alliance to Develop Antibody Therapies against Hospital-Acquired Infections
Daiichi Sankyo becomes MorphoSys's first collaborator for HuCAL PLATINUM®-based drug discovery in infectious diseases.
Tuesday, October 20, 2009
MorphoSys Announces Clinical Milestone in Cancer Program with Bayer Schering Pharma
Companies announce filling of the documentation to initiate a Phase 1 clinical trial with eighth HuCAL antibody.
Tuesday, September 08, 2009
MorphoSys and the University of Melbourne File new Patent Applications in MOR103 Program
MOR103 HuCAL antibody against human GM-CSF is currently in development for the treatment of rheumatoid arthritis.
Friday, July 03, 2009
MorphoSys Strengthens Patent Position on its Core Technologies in Japan
Patent covers CysDisplay® proprietary screening technology, a component of MorphoSys's proprietary HuCAL platform.
Thursday, June 18, 2009
MorphoSys Announces Extension of Antibody Alliance with Schering-Plough
The agreement grants Schering-Plough continued access to MorphoSys's antibody library HuCAL GOLD at its research site in Palo Alto, California.
Tuesday, June 16, 2009
Shionogi Extends Research Partnership with MorphoSys
Shionogi extends its current license agreement covering the use of MorphoSys's HuCAL technology in drug discovery, for three additional years.
Monday, September 29, 2008
MorphoSys Nominates First Pre-Development Program in Antibody Collaboration
MorphoSys announced today that it has exercised its first option to participate in the development of a therapeutic antibody program within its collaboration with Novartis.
Thursday, September 25, 2008
MorphoSys Announces Publication of First MOR103 Data
MorphoSys announced today the publication of a first data package for its most advanced proprietary drug development program MOR103, a fully human HuCAL antibody directed against GM-CSF, in the journal "Molecular Immunology".
Wednesday, September 03, 2008
Scientific News
Atriva Therapeutics GmbH Develops Innovative Flu Drug
Highly effective against seasonal and pandemic influenza.
Study Removes Cancer Doubt for Multiple Sclerosis Drug
Researchers from Queen Mary University of London are calling on the medical community to reconsider developing a known drug to treat people with relapsing Multiple sclerosis after new evidence shows it does not increase the risk of cancer as previously thought.
New Hope for Personalized Treatment of Eczema
Pharmaceutical researchers at Oregon State University have developed a new approach to treat eczema and other inflammatory skin disorders that would use individual tests and advanced science to create personalized treatments based on each person's lipid deficiencies.
Inroads Against Leukaemia
Potential for halting disease in molecule isolated from sea sponges.
Researchers Disguise Drugs As Platelets to Target Cancer
Researchers have for the first time developed a technique that coats anticancer drugs in membranes made from a patient’s own platelets.
HIV Patients Should Be Included in Early Clinical Trials of Anti-TB Drugs
Tuberculosis is the number one cause of death in HIV-infected patients in Africa and a leading cause of death in this population worldwide.
Combination Drug Therapy Shrinks Pancreatic Tumors In Mice
Two drugs that affect the structure and function of DNA have been found to block the growth of pancreatic tumor cells in mice, researchers hope the drugs can soon be tested in humans with the disease.
Seeking A Better Way To Design Drugs
NIH funds research at Worcester Polytechnic Institute to advance a new chemical process for more effective drug development and manufacturing.
Old Drug Performs New Tricks
Cambridge-led research reveals the powers of a "wonder drug" that has lain under the noses of doctors for 50 years.
Diabetes Drugs May Actually Release Sugar Into the Blood
A family of drugs used to treat Type 2 diabetes could promote the release of sugars into the blood - something the drugs are supposed to prevent, Cambridge scientists have claimed.
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,600+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,800+ scientific videos